The FDA has approved Rapaflo (silodosin, from Watson) for the treatment of benign prostatic hyperplasia (BPH). In two randomized, double-blind, placebo-controlled trials of 923 patients, Rapaflo relieved symptoms of BPH compared to placebo as measured by the International Prostate Symptom Score (IPSS).

Rapaflo is expected to launch in early 2009.

For more information call (800) 272-5525 or visit www.watson.com.